Form 4: Teva Director Sells $2.3M in Shares Under 10b5-1 Plan

Teva Pharmaceutical Industries Director Roberto Mignone sold 77,400 ordinary shares for approximately $2.3 million on December 16, 2025, under a pre-arranged 10b5-1 plan.

Summary

• Roberto Mignone, a Director of Teva Pharmaceutical Industries Ltd. (TEVA), sold 77,400 ordinary shares.
• The transaction occurred on December 16, 2025, at a weighted average price of $30.2409 per share, totaling approximately $2,341,641.96.
• The sale was executed pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-scheduled transaction.
• Following the sale, Mr. Mignone directly beneficially owns 105,315 ordinary shares.
• Additionally, 367,600 ordinary shares are held indirectly through Swiftcurrent Master Fund Ltd., where Mr. Mignone is the manager of the investment adviser, though he disclaims beneficial ownership except for his indirect pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a director's sale of shares can sometimes be viewed negatively, the explicit mention of the transaction being executed under a Rule 10b5-1(c) plan suggests it was a pre-scheduled event for personal financial management rather than a reaction to adverse company developments, thus mitigating negative sentiment.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, which demonstrates adherence to a pre-arranged trading strategy and can mitigate concerns about opportunistic insider trading.

Negatives

• A director selling a significant number of shares, even if pre-planned, reduces their direct equity stake in the company, which some investors may view as a slight negative signal.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.

Industry Context

This insider transaction report provides specific details about a director's share sale and does not directly offer insights into broader industry trends or competitive landscape.

Corporate Governance

Related Party Transactions

• Roberto Mignone's indirect beneficial ownership of 367,600 ordinary shares is through Swiftcurrent Master Fund Ltd., where he is the manager of Bridger Management, LLC, the investment adviser to the Fund. He disclaims beneficial ownership except for his indirect pecuniary interest.

Stakeholder Impact

• Shareholders may view the director's sale with scrutiny, though the 10b5-1 plan mitigates concerns about the timing of the sale.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Next Steps

• The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price within the reported range.

Key Dates

Recommendation

The director's sale of shares was executed under a Rule 10b5-1(c) plan, suggesting it was a pre-scheduled transaction for personal financial management rather than a reaction to new company developments. While insider sales are often scrutinized, the pre-planned nature mitigates immediate negative sentiment. Investors should 'hold' and continue to monitor company fundamentals and broader market conditions, as this single transaction does not provide sufficient grounds for a strong buy or sell recommendation.

Keywords

Teva Pharmaceutical Industries, TEVA, Roberto Mignone, Director, Share Sale, Insider Transaction, Form 4, 10b5-1 Plan, Pharmaceutical, Equity